Please ensure Javascript is enabled for purposes of website accessibility

Why Viking Therapeutics, Inc. Stock Cratered in March

By George Budwell – Apr 12, 2018 at 7:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Viking's shares finally cooled off last month, but that doesn't make them a buy.

What happened

Shares of Viking Therapeutics (VKTX -1.85%), a clinical-stage biotech developing treatments for endocrine and metabolic disorders, dropped by 30.1% last month, according to S&P Global Market Intelligence. What's all the fuss about?

Viking's shares have been on an epic tear over the last few months, thanks to a positive phase 2 trial for VK5211 as a potential treatment for patients recovering from surgery to repair hip fractures. The biotech's shares thus appear to be simply cooling off after this sizable move. 

Chalkboard chart of a positive trend turning negative.

Image source: Getty Images.

So what

Viking is in the process of advancing multiple early- to mid-stage drug candidates in the clinic. As such, it wasn't surprising to see the company take advantage of its rising share price to tap the public markets for a healthy $78 million over the past few months. Unfortunately, these public offerings came at the expense of early shareholders, with the company nearly doubling its outstanding share count from roughly 26 million at the end of the fourth quarter to about 51 million at the end of February. 

Now what

The big question for potential investors is whether or not the company is done diluting shareholders for the time being. Unfortunately, the answer to that question is almost certainly 'no.' Even after these latest capital raises, after all, Viking still had less than $85 million on its books at the end of February. That amount is nowhere near enough to advance VK5211 and its other earlier stage candidates at the same time. Viking is therefore either going to have to find a deep-pocketed partner or tap the markets yet again to meet its long-term financial needs. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Viking Therapeutics, Inc. Stock Quote
Viking Therapeutics, Inc.
VKTX
$2.66 (-1.85%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.